Table 9.
Effect of MAPK pathway inhibitors on TCS-induced increases in IL-1β secretion from PBMCs.
| MEK1/2 Pathway Inhibitor (PD98059) |
| 24 h | TCS secreted in pg/mL (mean±S.D.) | ||||
|---|---|---|---|---|---|
| [TCS] μM | F630 | F631 | F633 | F696 | F697 |
| 0 | 350±19 | 2300±22 | 3470±42 | 1158±24 | 3032±14 |
| 0 + PD | 309±15 | 1163±25 | 2554±33 | 186±30 | 540±25 |
| 1 | 650±19+ | 3950±45+ | 3321±6+ | 2293±61+ | 2661±50 |
| 1 + PD | 199±27 | 804±31 | 1005±18+ | 1115±69+ | 682±31+ |
| 2.5 | 1012±30+ | 4346±64+ | 5526±99+ | 2960±18+ | 7473±64+ |
| 2.5 + PD | 306±40 | 1817±26+ | 1682±28+ | 1103±48+ | 907±7+ |
| 5 | 1390±19+ | 11642±26+ | 6696±24+ | 5341±18+ | 11019±26+ |
| 5 + PD | 640±15+ | 3550±22+ | 4429±122+ | 2254±20+ | 4057±19+ |
| p38 Inhibitor (SB202190) |
| 24 h | TCS secreted in pg/mL (mean±S.D.) | ||||
|---|---|---|---|---|---|
| [TCS] μM | F630 | F631 | F633 | F696 | F697 |
| 0 | 130±47 | 3119±46 | 1325±27 | 2734±34 | 4486±19 |
| 0 + SB | 216±14 | 952±23 | 593±30 | 1010±43 | 2244±14 |
| 1 | 554±36+ | 2352±68 | 2304±38+ | 2021±256 | 2994±112 |
| 1 + SB | 270±54 | 1093±8 | 1071±26+ | 1372±6+ | 2748±26+ |
| 2.5 | 1856±28+ | 4404±20+ | 6084±23+ | 3273±59+ | 5173±108+ |
| 2.5 + SB | 550±54+ | 1518±23+ | 2189±23+ | 2996±27+ | 4890±54+ |
| 5 | 4212±28+ | 10198±20+ | 8852±27+ | 5627±22+ | 8248±44+ |
| 5 + SB | 941±51+ | 3624±23+ | 3361±23+ | 3443±87+ | 6519±38+ |
Values are mean±S.D. of triplicate determinations.
+
indicates a significant increase in secretion compared to the appropriate control cells, p<0.05